Telix Pharmaceuticals Ltd. has reached a deal to acquire a portfolio of potential imaging agents and other assets for up to $185 million, the company announced Monday. Inglewood, California-based biotechnology company ImaginAb is the seller, unloading a pipeline of drug candidates, technology platform and research facility. Telix noted that the acquired assets allow for “highly […]
